Overview

Open-Label, Randomised Parallel-Group Study

Status:
Withdrawn

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Ferring Pharmaceuticals

Treatments:

Androgens